当前位置:首页 - 行情中心 - 沃森生物(300142) - 财务分析 - 现金流量表

沃森生物

(300142)

  

流通市值:176.29亿  总市值:181.21亿
流通股本:15.56亿   总股本:15.99亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,140,953,138.4455,896,090.973,476,205,413.62,479,483,972.8
  收到的税费返还1,631,558.23-2,319,496.16-
  收到其他与经营活动有关的现金51,084,430.85,463,098.85119,205,826.0499,450,399.78
  经营活动现金流入小计1,193,669,127.43461,359,189.823,597,730,735.82,578,934,372.58
  购买商品、接受劳务支付的现金778,736,131.3457,915,823.661,844,648,011.241,446,009,634.04
  支付给职工以及为职工支付的现金198,170,171.69125,212,059.95454,811,257.82387,426,141.88
  支付的各项税费56,667,782.4323,612,414139,135,975.18116,522,292.41
  支付其他与经营活动有关的现金43,437,957.6616,293,815.05122,610,964.0669,571,662.88
  经营活动现金流出小计1,077,012,043.08623,034,112.662,561,206,208.32,019,529,731.21
  经营活动产生的现金流量净额116,657,084.35-161,674,922.841,036,524,527.5559,404,641.37
二、投资活动产生的现金流量:
  取得投资收益收到的现金--4,895,829.014,822,127.22
  处置固定资产、无形资产和其他长期资产收回的现金净额191,389827,624466,978.552,405
  投资活动现金流入小计191,389827,6245,362,807.514,874,532.22
  购建固定资产、无形资产和其他长期资产支付的现金141,478,824.7170,445,611.45550,029,878.5445,299,885.81
  投资支付的现金--22,000,00032,000,000
  支付其他与投资活动有关的现金--700,000,000700,000,000
  投资活动现金流出小计141,478,824.7170,445,611.451,272,029,878.51,177,299,885.81
  投资活动产生的现金流量净额-141,287,435.71-69,617,987.45-1,266,667,070.99-1,172,425,353.59
三、筹资活动产生的现金流量:
  吸收投资收到的现金2,440,000---
  其中:子公司吸收少数股东投资收到的现金2,440,000---
  取得借款收到的现金--38,216,439.238,216,439.2
  收到其他与筹资活动有关的现金--182,576.95182,576.95
  筹资活动现金流入平衡项目0-00
  筹资活动现金流入小计2,440,000-38,399,016.1538,399,016.15
  偿还债务支付的现金24,510,00020,000,000329,580,000104,610,000
  分配股利、利润或偿付利息支付的现金434,172,909.884,268,386.0940,940,003.2627,325,614.55
  其中:子公司支付给少数股东的股利、利润409,731,500---
  支付其他与筹资活动有关的现金745,691,685.763,084,13538,909,655.3124,430,997.58
  筹资活动现金流出小计1,204,374,595.6427,352,521.09409,429,658.57156,366,612.13
  筹资活动产生的现金流量净额-1,201,934,595.64-27,352,521.09-371,030,642.42-117,967,595.98
四、汇率变动对现金及现金等价物的影响1,233,445.5419,876.895,413,290.34-5,461,839.45
五、现金及现金等价物净增加额-1,225,331,501.46-258,625,554.49-595,759,895.57-736,450,147.65
  加:期初现金及现金等价物余额3,759,102,816.013,759,102,816.014,354,862,711.584,354,862,711.58
  期末现金及现金等价物余额2,533,771,314.553,500,477,261.523,759,102,816.013,618,412,563.93
补充资料:
  净利润-7,094,241.99-174,397,875.24-
  资产减值准备192,719,154.7-157,082,365.91-
  固定资产和投资性房地产折旧131,884,394.83-248,717,522-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧131,884,394.83-248,717,522-
  无形资产摊销63,213,823.7-114,875,013.27-
  长期待摊费用摊销9,993,117.25-23,020,888.53-
  处置固定资产、无形资产和其他长期资产的损失-130,387.03-1,767,057.21-
  固定资产报废损失602,963.92-967,178.5-
  公允价值变动损失-13,422,300-98,339,100-
  财务费用-8,569,362.17--7,743,187.6-
  投资损失486,057.34--5,025,931.85-
  递延所得税-7,437,726.37--5,815,718.72-
  其中:递延所得税资产减少1,557,420.75--1,112,955.95-
    递延所得税负债增加-8,995,147.12--4,702,762.77-
  存货的减少78,348,276.39-115,879,650.96-
  经营性应收项目的减少-28,432,302.07-781,300,754.09-
  经营性应付项目的增加-301,465,399.82--686,189,884.35-
  现金的期末余额2,533,771,314.55-3,759,102,816.01-
  减:现金的期初余额3,759,102,816.01-4,354,862,711.58-
  现金及现金等价物的净增加额-1,225,331,501.46--595,759,895.57-
公告日期2025-08-262025-04-262025-04-122024-10-26
审计意见(境内)标准无保留意见
TOP↑